Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Discovery Grants Program - Individual

École Polytechnique de Montréal

$33,000.00

Intensification and control of cell culture processes

FY 2023-24

Summary
Mammalian cell culture is the dominant expression platform for the production of monoclonal antibodies, recombinant proteins and vaccines. With several hundreds of antibody products currently in clinical trials and with the anticipated emergence of many blockbuster biosimilars, the biotherapeutic market is expected to continue growing exponentially in the next decade. For many of these new biotherapeutics, the ability to mass produce them in a cost-efficient fashion will be a critical factor for their successful translation to the clinic and market. Fed-batch remains the predominant production mode for large-scale biomanufacturing, since it allows to extend the production phase and reach higher product titers. However, prolonged culture duration often leads to undesired changes to product consistency and quality over time. Despite the critical implications of product heterogeneity, most upstream process development efforts still concentrate on cellular growth and productivity. This is mainly due to the lack of a systematic approach to monitor and modulate product quality during production. The central goal of this research program is to intensify the production of biotherapeutics by developing innovative, robust, scalable and cost-efficient high-cell density culture processes. The research will target an industrially relevant application, the production of monoclonal antibodies by Chinese Hamster Ovary (CHO) cells, as these cells are the main workhorse of the biopharmaceutical industry. More specifically, the research program will aim to i) develop intensified high cell-density culture processes that can achieve an optimum performance in terms of both high culture yield and product quality ii) develop an analytical approach to rapidly assess product quality during a culture and iii) devise and implement a model-based product control strategy. The methodology will be based on advanced and emerging analytical methods, including the use of mass spectrometry analysis and isotopic tracers for conducting metabolic studies and surface plasmon resonance (SPR) for rapid at-line assessment of product quality attributes. This research is expected to bring significant contributions to the field of biotherapeutics manufacturing, an area of considerable economic importance and having a direct impact on the health and welfare of Canadian citizens. By addressing the needs for improved and efficient bioprocesses, these research efforts can help to reduce the cost and time in getting much needed new biotherapeutics to the clinic and market, and will thus ultimately benefit both patients and industry. This research program will also contribute to the training of highly qualified personnel, which is recognized as an essential component to foster the development of the biomanufacturing industry in Canada.
Program
Discovery Grants Program - Individual
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
RGPIN-2021-04048
Name nom
Henry, Olivier
Department département
Chemical engineering
Organization id
64
Institution établissement
École Polytechnique de Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2023
Competition year année de concours
2021
Award amount
33000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1511
Committee name en
Materials and Chemical Engineering
Committee name fr
Génie chimique et des matériaux
Area of application code
500
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Manufacturing processes and products
Area of application fr
Procédés et produits industriels
Research subject code
9999
Research subject group en
Not available
Research subject group fr
Not available
Research subject en
Non disponible
Research subject fr
Non disponible
Application title
Intensification and control of cell culture processes
Keyword
Bioprocess control; Bioprocess monitoring; Cellular engineering; Fed-batch; Mammalian cell culture; Metabolic engineering; Monoclonal antibodies; Perfusion; Product glycosylation
Application summary
Mammalian cell culture is the dominant expression platform for the production of monoclonal antibodies, recombinant proteins and vaccines. With several hundreds of antibody products currently in clinical trials and with the anticipated emergence of many blockbuster biosimilars, the biotherapeutic market is expected to continue growing exponentially in the next decade. For many of these new biotherapeutics, the ability to mass produce them in a cost-efficient fashion will be a critical factor for their successful translation to the clinic and market. Fed-batch remains the predominant production mode for large-scale biomanufacturing, since it allows to extend the production phase and reach higher product titers. However, prolonged culture duration often leads to undesired changes to product consistency and quality over time. Despite the critical implications of product heterogeneity, most upstream process development efforts still concentrate on cellular growth and productivity. This is mainly due to the lack of a systematic approach to monitor and modulate product quality during production. The central goal of this research program is to intensify the production of biotherapeutics by developing innovative, robust, scalable and cost-efficient high-cell density culture processes. The research will target an industrially relevant application, the production of monoclonal antibodies by Chinese Hamster Ovary (CHO) cells, as these cells are the main workhorse of the biopharmaceutical industry. More specifically, the research program will aim to i) develop intensified high cell-density culture processes that can achieve an optimum performance in terms of both high culture yield and product quality ii) develop an analytical approach to rapidly assess product quality during a culture and iii) devise and implement a model-based product control strategy. The methodology will be based on advanced and emerging analytical methods, including the use of mass spectrometry analysis and isotopic tracers for conducting metabolic studies and surface plasmon resonance (SPR) for rapid at-line assessment of product quality attributes. This research is expected to bring significant contributions to the field of biotherapeutics manufacturing, an area of considerable economic importance and having a direct impact on the health and welfare of Canadian citizens. By addressing the needs for improved and efficient bioprocesses, these research efforts can help to reduce the cost and time in getting much needed new biotherapeutics to the clinic and market, and will thus ultimately benefit both patients and industry. This research program will also contribute to the training of highly qualified personnel, which is recognized as an essential component to foster the development of the biomanufacturing industry in Canada.